Bomedemstat (IMG-7289) is a potent, selective, irreversible and orally active LSD1 (KDM1A) inhibitor, increases H3K4 and H3K9 methylation.
Bomedemstat (IMG-7289) potentiated responses to PD-1 inhibition in a syngeneic model of SCLC, resulting in increased CD8+ T-cell infiltration and strong tumor growth inhibition.
Bomedemstat (IMG-7289) increased MHC class I expression in mouse SCLC tumor cells in vivo and augmented MHC-I induction by IFNγ and increased killing by tumor-specific T cells in cell culture.
Bomedemstat (IMG-7289) inhibits the production of inflammatory cytokines, impairs self-renewal and proliferation of neoplastic stem cells, and shows significant disease-modifying activities in multiple non-clinical models of myelofibrosis.
